7
Mar
2022
The Globally Integrated Biotech Is Down, But Not Out
“What else can you do? The entire isolation of Russia. Nowadays we see real solidarity of the whole world to cancel or stop any economic, cultural, technological, financial connections with Russia and we urge the same from the Drug Discovery community.” This was the message on Mar. 5 from Andrey Tolmachov, founder and CEO of Enamine Ltd., a Ukrainian chemistry... Read More
7
Mar
2022
SARS-CoV-2: Where Did It Come From and Where Does It Go Next?
We are once again in a period of pandemic optimism — June 2021 redux. I hope this is justified, but I am reminded of the “fool me once, fool me twice” saying. Over the past few weeks there have been four papers that examine viral infection dynamics between animals and humans — animal to human and back again (Zoonosis) that... Read More
7
Mar
2022
Peacetime vs Wartime CEO: A Useful Lens for Transformative Leaders?
As biotech execs cope with challenging market conditions (the XBI biotech index is off about 50% from its high of February 2021), I found myself revising a now-classic 2011 essay by venture capitalist Ben Horowitz of Andreessen-Horowitz, arguing that extremely challenging times require very different management skills, and a different leadership style. He describes and contrasts the approaches of what... Read More